The online version of this article (doi:10.1186/1475-2875-11-139) contains supplementary material, which is available to authorized users.
UDA has received travel grants from sanofi Aventis, sigma tau and Novartis. He has also received research funds from sanofi Aventis and sigma tau.
UDA and JPVG designed the sub-study. QB/SM/RG, AT/AY and CN/PP/AD/ET were responsible for the study implementation and data collection in Manhiça, Jinja/Tororo and Mbarara, respectively. PF, CVO and CVM conceived and performed the G6PD experiments. HvL managed the data. JPVG and CVM analysed the data. ARR supervised data analyses and results reporting. CVM, JPVG and UDA wrote the paper and all authors reviewed the manuscript.
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children <5 years of age with uncomplicated malaria.
This case–control study was performed in the context of a larger multicentre randomized clinical trial comparing safety and efficacy of four different ACT in children with uncomplicated malaria. Children, who after treatment experienced a haemoglobin drop ≥2 g/dl (cases) within the first four days (days 0, 1, 2, and 3), were compared with those without an Hb drop (controls). Cases and controls were matched for study site, sex, age and baseline haemoglobin measurements. Data were analysed using a conditional logistic regression model.
G6PD deficiency prevalence, homo- or hemizygous, was 8.5% (10/117) in cases and 6.8% (16/234) in controls (p = 0.56). The risk of a Hb drop ≥2 g/dl was not associated with either G6PD deficiency (adjusted odds ratio (AOR): 0.81; p = 0.76) or CDA treatment (AOR: 1.28; p = 0.37) alone. However, patients having both risk factors tended to have higher odds (AOR: 11.13; p = 0.25) of experiencing a Hb drop ≥2 g/dl within the first four days after treatment, however this finding was not statistically significant, mainly because G6PD deficient patients treated with CDA were very few. In non-G6PD deficient individuals, the proportion of cases was similar between treatment groups while in G6PD-deficient individuals, haemolytic anaemia occurred more frequently in children treated with CDA (56%) than in those treated with other ACT (29%), though the difference was not significant (p = 0.49).
The use of CDA for treating uncomplicated malaria may increase the risk of haemolytic anaemia in G6PD-deficient children.
Authors’ original file for figure 112936_2012_2108_MOESM1_ESM.gif
Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, Pamba A, Duparc S, Goh LE, Harrell E, Carter N, Ward SA, Greenwood B, Winstanley PA: Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2009, 81: 969-978. 10.4269/ajtmh.2009.09-0351. CrossRefPubMed
Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA: Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004, 363: 1843-1848. 10.1016/S0140-6736(04)16350-2. CrossRefPubMed
Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S, Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemdé R, Greenwood B, Ward SA, Winstanley PA: Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009, 4: e6682-10.1371/journal.pone.0006682. PubMedCentralCrossRefPubMed
World Health Organization: Antimalarial chlorproguanil-dapsone (LapDapTM) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (DacartTM) versus artemether-lumefantrine (Coartem) and confirmation of findings in a comparative trial of LapDapTM versus DacartTM. 2008, WHO, Switzerland
Beutler E: G6PD deficiency. Blood. 1994, 84: 3613-3636. PubMed
Beutler E, Duparc S, G6PD Deficiency Working Group: Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007, 77: 779-789. PubMed
ClinicalTrials.gov: [ http://www.clinicaltrials.gov]
The Four Artemisinin-Based Combinations (4ABC) group: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011, 8: e1001119-10.1371/journal.pmed.1001119. CrossRef
World Health Organization: Severe and complicated malaria. Trans R Soc Trop Med Hyg. 1990, 84: S1-S65. CrossRef
Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995, 52: 565-568. PubMed
Kotea R, Kaeda JS, Yan SL, Sem Fa N, Beesoon S, Jankee S, Ramasawmy R, Vulliamy T, Bradnock RW, Bautista J, Luzzatto L, Krishnamoorthy R, Mason PJ: Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Br J Haematol. 1999, 104: 849-854. 10.1046/j.1365-2141.1999.01230.x. CrossRefPubMed
Fanello CI, Karema C, Ngamije D, Uwimana A, Ndahindwa V, Van Overmeir C, Van Doren W, Curtis J, D'Alessandro U: A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2008, 102: 412-420. 10.1016/j.trstmh.2008.01.013. CrossRefPubMed
Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D: High risk of severe anaemia after chlorproguanil-dapsone + artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS One. 2008, 3: e4031-10.1371/journal.pone.0004031. PubMedCentralCrossRefPubMed
De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R: The role of the G6PD AEth376G/968 C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. Haematologica. 2006, 91: 262-263. PubMed
Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, Kirby PL, Woessner M, Neate C, Nyirenda M, Blencowe H, Dube-Mbeye Q, Kanyok T, Ward S, Molyneux M, Dunyo S, Winstanley PA: Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS One. 2008, 3: 1779-10.1371/journal.pone.0001779. CrossRef
Nieuwenhuis F, Wolf B, Bomba A, De Graaf P: Haematological study in Cabo Delgado province, Mozambique; sickle cell trait and G6PD deficiency. Trop Geogr Med. 1986, 38: 183-187. PubMed
Parikh S, Dorsey G, Rosenthal PJ: Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg. 2004, 71: 750-753. PubMed
Beutler E, Mitchell M: Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood. 1968, 32: 816-818. PubMed
Meissner PE, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, Müller O, Schirmer RH, Mockenhaupt FP, Bienzle U: Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. Br J Haematol. 2005, 131: 395-399. 10.1111/j.1365-2141.2005.05778.x. CrossRefPubMed
Ochong E, Bell DJ, Johnson DJ, D'Alessandro U, Mulenga M, Muangnoicharoen S, Van Geertruyden JP, Winstanley PA, Bray PG, Ward SA, Owen A: Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrob Agents Chemother. 2008, 52: 3883-3888. 10.1128/AAC.00431-08. PubMedCentralCrossRefPubMed
Krudsood S, Imwong M, Wilairatana P, Pukrittayakamee S, Nonprasert A, Snounou G, White NJ, Looareesuwan S: Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Trans R Soc Trop Med Hyg. 2005, 99: 142-149. 10.1016/j.trstmh.2004.07.001. CrossRefPubMed
- Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria
Carine Van Malderen
Jean-Pierre Van Geertruyden
Chantal Van Overmeir
Harry Van Loen
Umberto D’ Alessandro
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II